Kodiak Sciences Inc.

General Information
Business:

We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our most advanced product candidate is KSI-301, a biologic therapy built with our antibody biopolymer conjugate platform, or ABC Platform, which is designed to maintain potent and effective drug levels in ocular tissues. We believe that KSI-301, if approved, has the potential to become an important anti-VEGF therapy in wet age-related macular degeneration, or wet AMD, and diabetic retinopathy, or DR. KSI-301 and our ABC Platform were developed at Kodiak, and we own worldwide rights to those assets, including composition of matter patent protection for KSI-301. We have applied our ABC Platform to develop additional product candidates beyond KSI-301, including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate. We intend to progress these and other product candidates to address high-prevalence ophthalmic diseases.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 28
Founded: 2009
Contact Information
Address 2631 Hanover Street, Palo Alto, CA 94304, US
Phone Number (650) 281-0850
Web Address http://www.kodiak.com
View Prospectus: Kodiak Sciences Inc.
Financial Information
Market Cap $365.7mil
Revenues $0 mil (last 12 months)
Net Income $-32.48 mil (last 12 months)
IPO Profile
Symbol KOD
Exchange NASDAQ
Shares (millions): 9.0
Price range $10.00 - $10.00
Est. $ Volume $90.0 mil
Manager / Joint Managers Morgan Stanley/ BofA Merrill Lynch
CO-Managers Barclays/ Chardan
Expected To Trade: 10/4/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change